logo

For the Inventor, By the Inventor

Salisbury, United Kingdom

Gw Pharma Limited


USPTO Granted Patents = 66

% Expired Patents = 13.6



Trademarks = 4

Forward Citations = 2,753

Loading Chart...
Loading Chart...

73 inventors (with patents filed for the assignee):

goldMedal Geoffrey W Guy (32 out of 73 patents)

silverMedal Brian Anthony Whittle (17 out of 28 patents)

bronzeMedal Stephen Wright (17 out of 61 patents)

4.  Alice Mead (10 out of 12 patents)

5.  Colin Stott (9 out of 17 patents)

6.  Orrin Devinsky (8 out of 27 patents)

7.  Gary Stephens (8 out of 11 patents)

8.  Claire Williams (8 out of 12 patents)

9.  Rajiv Bobby Dave (7 out of 10 patents)

10.  Tetsuro Kikuchi (6 out of 25 patents)

11.  David Victor Downs (5 out of 5 patents)

12.  Vincenzo Di Marzo (4 out of 13 patents)

13.  Benjamin Whalley (4 out of 20 patents)

14.  Thomas Hill (4 out of 4 patents)

15.  Ben Whalley (4 out of 4 patents)


Core Competencies:
Phytocannabinoids
Cannabidiol
Cannabidivarin
Epilepsy Treatment
Pharmaceutical Formulation
Neuroprotective Agents
Cancer Treatment
Pain Management
Nausea Treatment
Inflammatory Diseases
Mental Disorders
Extraction Processes

66 patents:

1. 12121499 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2024-10-22),
2. 12023305 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2024-07-02),
3. 11413266 - Use of cannabinoids in the treatment of inflammatory skin diseases (2022-08-16),
4. 11318109 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2022-05-03),
5. 10807777 - Pharmaceutical formulation (2020-10-20),
6. 10799467 - Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy (2020-10-13),
7. 10758514 - Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour (2020-09-01),
8. 10729665 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2020-08-04),
9. 10653641 - Use of cannabinoids in the treatment of mental disorders (2020-05-19),
10. 10538373 - Pharmaceutical formulation (2020-01-21),
11. 10258580 - Cannabinoids for use in the treatment of neurodegenerative diseases or disorders (2019-04-16),
12. 10195159 - Processes and apparatus for extraction of active substances and enriched extracts from natural products (2019-02-05),
13. 10179683 - Pharmaceutical formulation (2019-01-15),
14. 10137095 - Use of cannabinoids in the treatment of epilepsy (2018-11-27),
15. 10111840 - Use of cannabinoids in the treatment of epilepsy (2018-10-30),
GW Pharma Limited is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of cannabinoid prescription medicines. With a focus on harnessing the therapeutic potential of cannabinoids, GW Pharma conducts extensive research and clinical trials to bring innovative treatments to patients. Their products address various medical conditions, including epilepsy, multiple sclerosis, and childhood-onset epilepsy disorders. Headquartered in the United Kingdom, GW Pharma operates globally, improving patients' lives through their commitment to scientific excellence and dedication to providing high-quality and safe medications.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Gw Pharma Limited
66 Patents

#2 in Salisbury

#277 in United Kingdom

#11,138 in the World

Salisbury, GB
Salisbury, United Kingdom

Gw Pharma Limited

Forward Citations = 2,753

73 inventors:

goldMedal Geoffrey W Guy (32 out of 73 patents)

silverMedal Brian Anthony Whittle (17 out of 28 patents)

bronzeMedal Stephen Wright (17 out of 61 patents)

4.  Alice Mead (10 out of 12 patents)

5.  Colin Stott (9 out of 17 patents)

Please report any incorrect information to [email protected]
Loading…